Hydroxyurea Medac

Hydroxycarbamide, the active ingredient in Hydroxyurea Medac, is an antimetabolite presented as an oral tablet for oral use. It is employed in the management of certain hematologic malignancies and blood disorders, including chronic myelogenous leukemia, sickle cell disease, polycythemia vera, and essential thrombocythemia.

GNH USA supplies Hydroxyurea Medac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet clinical demand across multiple regions.

Hydroxyurea is an antimetabolite used in the treatment of several hematologic conditions. - Chronic myelogenous leukemia: reduces leukemic cell proliferation and helps achieve hematologic remission. - Sickle cell disease: decreases frequency of vaso‑occlusive crises by raising fetal hemoglobin levels. - Polycythemia vera: lowers elevated red blood cell mass, helping control hematocrit. - Essential thrombocythemia: reduces platelet counts and mitigates thrombotic risk.

Hydroxyurea may cause a range of adverse reactions, varying from mild to severe. Common Side Effects: - Bone marrow suppression: anemia, neutropenia, or thrombocytopenia leading to fatigue or infection risk. - Gastrointestinal upset: nausea, vomiting, or abdominal discomfort that may affect appetite. - Skin changes: hyperpigmentation or rash, often mild and reversible. Serious or Rare Side Effects: - Severe myelosuppression: life‑threatening pancytopenia requiring transfusion or growth‑factor support. - Pulmonary toxicity: interstitial pneumonitis or fibrosis presenting with cough and dyspnea. - Leg ulcers: painful skin ulceration, especially in sickle cell patients, that may need specialized wound care.

When prescribing hydroxyurea, clinicians should observe several precautionary measures to minimize risks. - Baseline blood counts: obtain complete blood count before initiation and monitor regularly. - Renal function: assess serum creatinine and adjust use in impaired kidney function. - Hepatic function: evaluate liver enzymes and consider dose modification if elevated. - Pregnancy and lactation: avoid use unless benefits outweigh potential fetal risks; discuss with obstetric specialist. - Drug-specific contraindications: discontinue if severe myelosuppression or hypersensitivity occurs. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture and light.

Hydroxyurea can interact with several medicines, altering its efficacy or toxicity. Major Interactions (Avoid): - Antiretroviral protease inhibitors: may increase hydroxyurea plasma levels, raising toxicity risk. - Azathioprine or mercaptopurine: additive bone‑marrow suppression leading to severe cytopenias. Moderate Interactions (Monitor Closely): - NSAIDs: can enhance renal toxicity, requiring renal function monitoring. - Phenytoin: may reduce hydroxyurea effectiveness by inducing metabolism. - Live vaccines: immunosuppression from hydroxyurea may diminish vaccine response.